Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 8/20 | 0.37 |
| ▸ | MAPK3 | P27361 | 7/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.36 |
| ▸ | RELA | Q04206 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18608901 | 0.78 | MAPT (0.39) | MAPK1MAPTNPC1NFKB1RAB9A | |
| SCHEMBL24911 | 0.76 | MAPT (0.38) | MAPK1MAPTNPC1NFKB1RAB9A | |
| SCHEMBL24910 | 0.76 | MAPT (0.38) | MAPK1MAPTNPC1NFKB1RAB9A | |
| SCHEMBL14519206 | 0.75 | CYP11B2 (0.37) | CYP19A1CYP11B2MAPTALDH1A1LMNA | |
| SCHEMBL6174408 | 0.75 | CYP11B1 (0.44) | CYP19A1CYP11B2MAPTALDH1A1LMNA | |
| SCHEMBL5131390 | 0.74 | RAB9A (0.43) | BRAFMAPK3MAPK1CYP19A1CYP11B2 | |
| SCHEMBL5131394 | 0.74 | RAB9A (0.43) | BRAFMAPK3MAPK1CYP19A1CYP11B2 | |
| SCHEMBL6606901 | 0.72 | MAPT (0.42) | CYP19A1CYP11B2MAPTNPC1NFKB1 | |
| SCHEMBL6606892 | 0.72 | MAPT (0.42) | CYP19A1CYP11B2MAPTNPC1NFKB1 | |
| SCHEMBL13606738 | 0.70 | MAPT (0.47) | MAPK1MAPTNPC1NFKB1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108615-A1 | Imidazole-2-Carboxamide Derivatives as Raf Kinase Inhibitors | SMITHKLINE BEECHAM P.L.C | 2008-05-08 | — | — | US | disclosed |
| US-7282500-B2 | Imidazole-2-carboxamide derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-10-16 | — | — | US | disclosed |
| US-20070135433-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | DEAN DAVID K | 2007-06-14 | — | — | US | disclosed |
| US-7199137-B2 | Imidazole derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2007-04-03 | — | — | US | disclosed |
| US-20050176740-A1 | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor | SMITHKLINE BEECHAM CORPORATION | 2005-08-11 | — | — | US | disclosed |
| US-20040127496-A1 | Imidazole-2-carboxamide derivatives as raf kinase inhibitors | DEAN DAVID KENNETH (GB) | 2004-07-01 | — | — | US | disclosed |
| US-20040038964-A1 | Imidazole derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-26 | — | — | US | disclosed |
| EP-1318992-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024680-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176740-A1 | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor | BRAF, KRAS, NRAS | BRAF 1/4885MAPK3 488/4885MAPK1 639/4885 |
| US-20070135433-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885MAPK3 95/4885MAPK1 90/4885 |
| US-20040038964-A1 | Imidazole derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885MAPK3 77/4885MAPK1 55/4885 |
| US-20040127496-A1 | Imidazole-2-carboxamide derivatives as raf kinase inhibitors | RAF1, BRAF, ARAF | BRAF 2/4885MAPK3 68/4885MAPK1 29/4885 |
| US-20080108615-A1 | Imidazole-2-Carboxamide Derivatives as Raf Kinase Inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885MAPK3 62/4885MAPK1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.